FGFR2 and cholangiocarcinoma: Several FGFR-selective TKIs are currently under clinical investigation in iCCA, such as pemigatinib25, infigratinib (BGJ398)26, erdafitinib27, derazantinib28, or TAS-12029, with pemigatinib being the first drug that received approval by the FDA for CCA with FGFR2 fusion genes14.